

Biplab Bose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6040393/publications.pdf>

Version: 2024-02-01

16
papers

204
citations

1307594

7
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

386
citing authors

#	ARTICLE	IF	CITATIONS
1	DEBay: A computational tool for deconvolution of quantitative PCR data for estimation of cell type-specific gene expression in a mixed population. <i>Heliyon</i> , 2020, 6, e04489.	3.2	0
2	The Mathematics of Phenotypic State Transition: Paths and Potential. <i>Journal of the Indian Institute of Science</i> , 2020, 100, 451-464.	1.9	5
3	Morphological State Transition Dynamics in EGF-Induced Epithelial to Mesenchymal Transition. <i>Journal of Clinical Medicine</i> , 2019, 8, 911.	2.4	43
4	Peptides derived from a short stretch of diphtheria toxin bind to heparin-binding epidermal growth factor-like growth factor. <i>Toxicon</i> , 2019, 169, 109-116.	1.6	1
5	Percolation in a reduced equilibrium model of planar cell polarity. <i>Physical Review E</i> , 2019, 100, 032408.	2.1	3
6	Receptor-Mediated Enhanced Cellular Delivery of Nanoparticles Using Recombinant Receptor-Binding Domain of Diphtheria Toxin. <i>Molecular Pharmaceutics</i> , 2017, 14, 23-30.	4.6	12
7	Autoregulation and Heterogeneity in Expression of Human Cripto-1. <i>PLoS ONE</i> , 2015, 10, e0116748.	2.5	6
8	A new peptide (Ruviprase) purified from the venom of <i>Daboia russelii russelii</i> shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa. <i>Biochimie</i> , 2014, 105, 149-158.	2.6	35
9	Recombinant Receptor-Binding Domain of Diphtheria Toxin Increases the Potency of Curcumin by Enhancing Cellular Uptake. <i>Molecular Pharmaceutics</i> , 2014, 11, 208-217.	4.6	5
10	Systems biology: A biologist's viewpoint. <i>Progress in Biophysics and Molecular Biology</i> , 2013, 113, 358-368.	2.9	15
11	Human recombinant Cripto-1 increases doubling time and reduces proliferation of HeLa cells independent of pro-proliferation pathways. <i>Cancer Letters</i> , 2012, 318, 189-198.	7.2	16
12	Generation and characterization of a high-affinity chimaeric antibody against hepatitis B surface antigen. <i>Biotechnology and Applied Biochemistry</i> , 2006, 43, 93.	3.1	1
13	Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 060606032707043-???	2.8	1
14	Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection. <i>Immunology</i> , 2005, 116, 172-183.	4.4	35
15	High affinity mouse-human chimeric Fab against Hepatitis B surface antigen. <i>World Journal of Gastroenterology</i> , 2005, 11, 7569.	3.3	5
16	Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv. <i>Molecular Immunology</i> , 2003, 40, 617-631.	2.2	21